期刊
CANCER CELL
卷 1, 期 2, 页码 133-143出版社
CELL PRESS
DOI: 10.1016/S1535-6108(02)00032-6
关键词
-
资金
- NATIONAL CANCER INSTITUTE [R01CA051001, R01CA036401, P30CA021765, R01CA078224, R29CA051001, R37CA036401, P01CA071907] Funding Source: NIH RePORTER
- NCI NIH HHS [CA36401, CA-21765, P01 CA71907-06, CA78224, CA51001] Funding Source: Medline
Treatment of pediatric acute lymphoblastic leukemia (ALL) is based on the concept of tailoring the intensity of therapy to a patient's risk of relapse. To determine whether gene expression profiling could enhance risk assignment, we used oligonucleotide microarrays to analyze the pattern of genes expressed in leukemic blasts from 360 pediatric ALL patients. Distinct expression profiles identified each of the prognostically important leukemia subtypes, including T-ALL, E2A-PBX1, BCR-ABL, TEL-AML1, MLL rearrangement, and hyperdiploid >50 chromosomes. In addition, another ALL subgroup was identified based on its unique expression profile. Examination of the genes comprising the expression signatures provided important insights into the biology of these leukemia subgroups. Further, within some genetic subgroups, expression profiles identified those patients that would eventually fail therapy. Thus, the single platform of expression profiling should enhance the accurate risk stratification of pediatric ALL patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据